ESC 365 - Potential candidates for PCSK9 inhibitors among patients with stable coronary artery disease presumed to be on maximally tolerated hypolipidemic treatment

ESC Premium Access

Potential candidates for PCSK9 inhibitors among patients with stable coronary artery disease presumed to be on maximally tolerated hypolipidemic treatment

Session: Poster session 1 - Lipids

Topic: Lipids (Epidemiology and Prevention)

Speaker: Professor L. Rallidis (Athens, GR)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Professor Loukianos Rallidis

Attikon University Hospital, Athens (Greece)

0 follower

14 more presentations in this session

Associations between very low concentrations of LDL-cholesterol and health outcomes in the reasons for geographical and racial differences in stroke (REGARDS) Study

Speaker: Professor P. Penson (Liverpool, GB)

Cholesterol efflux capacity and incident atherosclerotic cardiovascular disease events in a Japanese general population

Speaker: Doctor M. Ogura (Urayasu, JP)

Undertreatment of female patients in lipid-lowering for secondary prevention in Europe, Canada, South-Africa, Middle East and China: results of the dyslipidemia international study (dysis)

Speaker: Doctor A. Gitt (Ludwigshafen, DE)

Comparison of plaque microstructures between two high-intensity statin therapies: rosuvastatin versus atorvastatin

Speaker: Doctor S. Honda (Osaka, JP)

Sex-related differences in clinical characteristics, low-density lipoprotein cholesterol control and cardiovascular outcomes in familial hypercholesterolemia.

Speaker: Doctor T. Doi (Herlev, DK)

Access the full session

Poster session 1 - Lipids

Speakers: Professor L. Rallidis, Professor P. Penson, Doctor M. Ogura, Doctor A. Gitt, Doctor S. Honda...

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources